PDCD1 and colorectal carcinoma: The primary goal was to assess the prevalence of Roseburia intestinalis in individuals with CRC, scrutinize its impact in animal models of CRC, and unveil the underlying mechanisms through which Roseburia intestinalis and its metabolite, butyrate, influence tumor development and response to anti-PD-1 immunotherapy (28).